Latest Ratios: P/E Ratio -90.0x · EV/EBITDA N/A · ROE -36.6%. (2013–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $4.1B | $5.7B | $2.8B | $3.3B | $2.8B | $3.5B | $6.6B | $1.7B | $1.7B | $1.3B | $159M |
| Enterprise Value | $4.6B | $6.2B | $3.1B | $3.4B | $2.9B | $3.4B | $6.6B | $1.8B | $1.7B | $1.3B | $139M |
| P/E Ratio → | -89.99 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 5.50 | 7.60 | 4.75 | 6.63 | 6.82 | 10.69 | 24.83 | 8.02 | 11.27 | 12.79 | 2.47 |
| P/B Ratio | 26.21 | 37.18 | 30.94 | 15.55 | 11.69 | 12.35 | 19.27 | 12.70 | 30.49 | 15.94 | 1.71 |
| P/FCF | 119.04 | 164.50 | — | — | — | — | — | — | — | — | — |
| P/OCF | 50.82 | 70.23 | 829.78 | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 8.26 | 5.29 | 6.82 | 6.95 | 10.66 | 24.96 | 8.52 | 11.37 | 13.05 | 2.17 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | 178.85 | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 70.6% | 70.6% | 68.9% | 67.3% | 68.5% | 66.2% | 73.5% | 75.5% | 73.7% | 71.5% | 67.4% |
| Operating Margin | -4.9% | -4.9% | -19.5% | -25.4% | -27.7% | -31.0% | -16.5% | -25.5% | -31.0% | -27.8% | -24.3% |
| Net Profit Margin | -6.0% | -6.0% | -19.1% | -25.0% | -28.3% | -31.4% | -16.5% | -25.4% | -34.2% | -30.0% | -32.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -36.6% | -36.6% | -75.3% | -54.9% | -44.7% | -32.6% | -18.4% | -57.5% | -75.2% | -34.6% | -22.6% |
| ROA | -4.6% | -4.6% | -16.6% | -28.0% | -25.5% | -20.8% | -10.7% | -25.6% | -39.9% | -21.9% | -23.7% |
| ROIC | -5.2% | -5.2% | -24.3% | -31.5% | -30.4% | -23.2% | -10.6% | -26.3% | -39.4% | -23.3% | — |
| ROCE | -4.4% | -4.4% | -20.2% | -36.5% | -31.0% | -24.3% | -12.5% | -31.9% | -45.3% | -23.3% | -20.2% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 4.79 | 4.79 | 8.11 | 0.62 | 0.55 | 0.42 | 0.36 | 0.95 | 0.64 | 0.43 | 0.35 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 3.24 | 3.49 | 0.45 | 0.22 | -0.04 | 0.10 | 0.80 | 0.27 | 0.32 | -0.21 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | 14.34 | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -2.80 | -2.80 | -7.79 | -32.60 | -27.01 | -85.39 | -27.70 | -32.17 | -15.16 | -7.78 | -5.44 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.63 | 4.63 | 5.82 | 2.15 | 3.24 | 3.48 | 5.75 | 3.32 | 3.52 | 5.72 | 8.98 |
| Quick Ratio | 4.48 | 4.48 | 5.70 | 2.02 | 3.07 | 3.36 | 5.67 | 3.24 | 3.45 | 5.64 | 8.87 |
| Cash Ratio | 3.84 | 3.84 | 4.83 | 1.25 | 2.39 | 2.72 | 5.10 | 2.70 | 2.59 | 4.89 | 8.02 |
| Asset Turnover | — | 0.73 | 0.64 | 1.14 | 0.92 | 0.70 | 0.52 | 0.70 | 1.23 | 0.74 | 0.46 |
| Inventory Turnover | 10.16 | 10.16 | 13.13 | 11.51 | 8.53 | 10.64 | 13.23 | 13.00 | 18.81 | 16.76 | 15.02 |
| Days Sales Outstanding | — | 36.98 | 49.30 | 45.55 | 44.34 | 52.50 | 41.20 | 40.60 | 49.05 | 47.69 | 53.58 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | 0.8% | 0.6% | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.9% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.2% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.9% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.2% | 0.0% | 0.0% |
| Shares Outstanding | — | $32M | $31M | $31M | $30M | $29M | $28M | $25M | $24M | $23M | $5M |
CMS reimbursement rate sensitivity
Based on current market data, IRTC trades at a price-to-sales multiple of 5.23, which suggests that investors are pricing in significant future expansion of the company's AI-driven diagnostic platform rather than current earnings, especially when compared to more mature medical technology peers with established profitability profiles.
The lack of a positive P/E ratio and the elevated P/B of 24.91 indicate that the market is valuing the company's intangible assets and proprietary data moat over its current bottom-line performance. This valuation appears to assume a rapid transition to sustained profitability, which may be aggressive given the ongoing regulatory and reimbursement uncertainties inherent in the ambulatory cardiac monitoring space.
According to recent financial statements, IRTC's ROIC has remained consistently negative, with a 2026Q1 figure of -1.9%, highlighting the company's ongoing struggle to generate returns on invested capital that exceed its cost of capital while scaling its diagnostic infrastructure and clinical operations team.
The persistent negative ROIC suggests that the capital deployed into R&D and market expansion has yet to reach an inflection point where it generates meaningful economic value. Investors should monitor whether the company's shift toward international markets can improve asset utilization and eventually drive returns into positive territory.
As reported in quarterly filings, the company's cash conversion cycle reached 62 days in 2026Q1, reflecting persistent friction in the billing and collection process that complicates the company's ability to translate its high-growth revenue model into consistent, self-sustaining operational cash flow for its core diagnostic services.
The variability in DSO, which fluctuated between 33 and 54 days over the last ten quarters, suggests that the company faces ongoing challenges in navigating complex insurance reimbursement channels. This inefficiency in working capital management appears to be a structural drag on liquidity, necessitating careful monitoring of unbilled receivables.
Based on the 2026Q1 balance sheet, IRTC maintains a debt-to-equity ratio of 4.52, which indicates that the company's capital structure is heavily reliant on external financing to support its growth initiatives, leaving it potentially vulnerable to shifts in interest rates or capital market conditions.
The high leverage, combined with negative interest coverage ratios in several recent periods, suggests that debt service could become a significant burden if operational cash flow does not improve rapidly. This capital structure warrants further investigation, as it limits the company's ability to absorb potential regulatory or reimbursement-related shocks.
The price-to-earnings ratio is a fundamentally misapplied metric for IRTC, as it obscures the company's true operational performance by failing to account for significant non-cash stock-based compensation expenses that consistently distort GAAP net income and mask the underlying cash burn of the business model.
Analysts should instead focus on adjusted EBITDA or free cash flow metrics to better understand the company's ability to fund its operations. Relying on P/E in this context may lead to an inaccurate assessment of the company's valuation, as it ignores the substantial dilution and non-cash costs inherent in the current growth strategy.
Includes 30+ ratios · 13 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying IRTC stock.
iRhythm Technologies, Inc.'s current P/E ratio is -90.0x. This places it at the 50th percentile of its historical range.
iRhythm Technologies, Inc.'s return on equity (ROE) is -36.6%. The historical average is -84.5%.
Based on historical data, iRhythm Technologies, Inc. is trading at a P/E of -90.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
iRhythm Technologies, Inc. has 70.6% gross margin and -4.9% operating margin.